Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS) header
Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS) profile picture

$PTX is a clinical stage oncology company developing personalised medicine approaches to cancer, including cellular and targeted therapies.

Melbourne, Australia
Joined December 2014
Photo by Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS)Photo by Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS)Photo by Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS)Photo by Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS)Photo by Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS)Photo by Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS)Photo by Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS)Photo by Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS)Photo by Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS)Photo by Prescient Therapeutics PTX, Novel Cancer Therapies (@PTX_AUS)
Prescient Therapeutics (ASX: PTX) is pleased to provide its Activities Report and Appendix 4C for the quarter ended 30 September 2026. Following this, CEO, James McDonnell will host an Investor Briefing on Wednesday, 21st October at 11am (AEDT). Register: ap1.hubs.ly/H01rpb_0
1
49
🔴 @StockheadAU's Tylah Tully hosts Prescient Therapeutics (ASX: PTX) CEO, James McDonnell to discuss the company's first planned Dose Optimisation Committee (DOC) review in its Phase 2a study of PTX-100. ▶️ Watch now: ap1.hubs.ly/H01n30V0 #Biotech #CancerTreatment
1
55
🔴 Prescient Therapeutics (ASX: PTX) CEO, James McDonnell, recently sat down with @Stockhead to explain the process of the PTX-100 drug trial from concept to commercialisation. ▶️ Watch now: ap1.hubs.ly/H01mN2R0
1
75
🟠 @SmallCapsASX, James Whelan, recently held a detailed interview with Prescient Therapeutics (ASX: PTX) CEO, James McDonnell discussing where next for the company, PTX-100 and more. Watch now ▶️ ap1.hubs.ly/H01mssh0 🔗 Stay up-to-date: ap1.hubs.ly/H01msrP0
35
📰 @australian recently covered Prescient Therapeutics (ASX: PTX) journey to advance their first-in-class cancer drug, PTX-100, as big pharma looks to licensing and acquisitions to replenish drug pipelines ahead of major patent cliffs. Read the article 🔗 ap1.hubs.ly/H01ms190
1
42
📰 The @australian Article: Prescient’s PTX-100 drug trial hits key review milestone with 10 evaluable patients now enrolled in each dosing arm, PTX-100 is on track for its first dose optimisation review in December 2026.  Read the full article 🔗 ap1.hubs.ly/H01ly940
1
39
Announcement 📢 PTX-100 CTCL Phase 2a study reaches dose optimisation review milestone; on track for December 2026. CEO, James McDonnell will host an online investor briefing on 4th September at 11am discussing what this means for the company. Register 🔗 ap1.hubs.ly/H01lvn_0
1
54
Prescient Therapeutics targets cancer with world-first GGTase-1 inhibitor*, now in Phase 2a trials for rare blood cancer CTCL. Read more 👉 ap1.hubs.ly/H01k8My0   *Based on public data  #Health #Biotech
54
Prescient Therapeutics (ASX: PTX) is pleased to provide its Activities Report & Appendix 4C for the quarter ended 30 June 2026. Following this, CEO, James McDonnell will host an Investor Briefing on 3rd August at 11am (AEST). Register 🔗 ap1.hubs.ly/H018f_90 #CancerTreatment
2
255
$PTX CEO James McDonnell is in San Diego attending BIO International Convention 2026, one of the largest gatherings of biotechnology leaders, investors & potential partners as $PTX advances PTX-100, the world's first GGTase-1 inhibitor in clinical development. #BIO2026 #ASX #PTX
1
121
Prescient Therapeutics (ASX:PTX) is pleased to announce the appointment of Dr Rosalind Wilson as Chief Medical Officer. Read more 👉 ap1.hubs.ly/y0Z7Th0 “I look forward to working with the team to advance these programs and unlock their full potential,” said Dr Wilson.
47
Prescient Therapeutics (ASX:PTX) CEO, James McDonnell recently discussed Prescient's collaboration with CSIRO. Watch now ▶ ️ap1.hubs.ly/y0WVt30 🔗 Stay up-to-date on Prescient’s news and announcements: ap1.hubs.ly/y0WVs90 #Biotech #CancerTherapies #CancerTreatment
1
53
Prescient Therapeutics (ASX: PTX) recently held an insightful Investor Briefing with CEO, James McDonnell. James discussed why the FDA has fast tracked PTX-100, how our first-in-class technology could apply to 22% of all cancer cases, and more. Watch now: ap1.hubs.ly/y0RSgj0
48
Prescient Therapeutics (ASX: PTX) is pleased to provide its Activities Report and Appendix 4C for the quarter ended 31 March 2026. CEO, James McDonnell will host an Investor Briefing on 5 May at 12pm (AEST). Register 🔗 ap1.hubs.ly/y0PByq0 #Biotech #Health #CancerTreatment
53
Prescient Therapeutics (ASX: PTX) is pleased to release an update for the quarter ending 31 December 2025. James McDonnell will be hosting an Investor Briefing on 4th February at 11am (AEDT). Register 🔗 ap1.hubs.ly/y0y8qF0 View announcement 🔗 ap1.hubs.ly/y0y82m0
2
85
As we begin an exciting new year, Prescient Therapeutics (ASX: PTX) CEO, James McDonnell, caught up with @proactive_au to discuss what investors can expect in 2026. Watch now 👉 ap1.hubs.ly/y0tVxW0 🔗 Stay up-to-date on news: ap1.hubs.ly/y0tV1F0 #Biotech
1
116
Special Report 📣 $PTX has raised $3m in a placement to sophisticated and professional investors following a $6.8m SPP for a total $9.8m to advance its pioneering cancer treatment therapy. Read more 👉 ap1.hubs.ly/y08gNc0 #Biotech #Health
1
134
Prescient Therapeutics $PTX is pleased to provide its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the June 2025 quarter. View the announcement 👉 ap1.hubs.ly/y087Vt0 #Biotech #Health #CancerTherapies #CancerTreatment
1
106
Special Report📣 $PTX has entered a critical stage where clinical data, regulatory support & commercial potential begin to converge in a defining moment for a biotech company aiming to bring a new therapy to market. Read more @australian👉ap1.hubs.ly/y082480 #Health #Biotech
1
6
295
Gain insights on Prescient’s advanced cancer drug PTX-100, which is in its all-important Phase 2 clinical trials, & working to improve the lives of people suffering from cancers of unmet need👉 ap1.hubs.ly/y07XPR0 🔗 Receive updates on $PTX: ap1.hubs.ly/y07XRw0 #Biotech
1
85